Source: Annual Congress 2002 - Management of tuberculosis in adults and children
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
I. A. Vassilieva, L. N. Tchernousova (Moscow, Russia). Treatment efficacy of MDR TB based on drug susceptibility testing with microchip technology. Eur Respir J 2002; 20: Suppl. 38, 3513

Member's Comments

No comment yet.

Related content which might interest you: The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis Source: Eur Respir J , 49 (4)  1602215; DOI: 10.1183/13993003.02215-2016 Year: 2017 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013 The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR – TB in Iran Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Treatment out-come in acquired drug resistance tuberculous patients receiving tailored regimen based on sensitivity report Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 569-571 Year: 2015 The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection Source: Eur Respir J 2015; 45: 571-574 Year: 2015